Phase II Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia Vera.
Phase of Trial: Phase II
Latest Information Update: 09 Feb 2018
At a glance
- Drugs Erlotinib (Primary)
- Indications Polycythaemia vera
- Focus Pharmacogenomic; Therapeutic Use
- 19 May 2014 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 10 Dec 2013 Results presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.
- 03 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History